LSL Pharma GroupTSXV:LSL 50 EBIT per Share is C$-0.02 as of Mar. 2026. GuruFocus rates TSXV:LSL with a GF Score™ of 50/100 and a GF Value™ of C$0.73 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 811 Drug Manufacturers companies, LSL Pharma Group ranks better than 82.37% on this metric.
LSL Pharma Group's EBIT per Share for the
three
months ended in Mar. 2026 was C$-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.02.
During the past 12 months, the average EBIT per Share Growth Rate of LSL Pharma Group was -700.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 37.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for LSL Pharma Group's EBIT per Share or its related term are showing as below:
TSXV:LSL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 37.5 Med: 37.5 Max: 37.5
Current: 37.5
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of LSL Pharma Group was 37.50% per year. The lowest was 37.50% per year. And the median was 37.50% per year.
TSXV:LSL's 3-Year EBIT Growth Rate is ranked better than 82.37% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs TSXV:LSL: 37.50
LSL Pharma Group's EBIT for the
three
months ended in Mar. 2026 was C$-1.91 Mil.
LSL Pharma Group (TSXV:LSL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
LSL Pharma Group EBIT per Share Related Terms
LSL Pharma Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for LSL Pharma Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSL Pharma Group (TSXV:LSL) has a EBIT per Share of C$-0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on LSL Pharma Group and its competitors. According to the industry distribution chart, LSL Pharma Group ranks #143 out of 811 companies in the Drug Manufacturers industry, placing it in the top 17.6%.
Is LSL Pharma Group's EBIT per Share too high?
LSL Pharma Group's current EBIT per Share is C$-0.02. Based on the distribution chart, LSL Pharma Group ranks #143 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, LSL Pharma Group has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, LSL Pharma Group ranks #143 out of 811 companies for EBIT per Share. This places LSL Pharma Group in the top 18% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on LSL Pharma Group and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LSL Pharma Group's current EBIT per Share is C$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.73, compared to a current price of C$0.32 — trading 56.8% below its estimated fair value. The current EBIT per Share is C$-0.02. LSL Pharma Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current EBIT per Share is C$-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?
Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued.
The current stock price of C$0.32 is trading 56.8% below its estimated GF Value™ of C$0.73.
GuruFocus considers LSL Pharma Group to be Possible Value Trap.
Key valuation signals for TSXV:LSL:
EBIT per Share: C$-0.02
GF Value™: C$0.73 vs. price of C$0.32 (56.8% below fair value)
No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
50GF Score
Get the complete analysis for TSXV:LSL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:LSL has been successfully added to your 
